{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:09:21Z","timestamp":1791155361477,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2002,6,28]],"date-time":"2002-06-28T00:00:00Z","timestamp":1025222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2002,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The current randomized, multicenter, Phase III trial was conducted to determine whether the disease free interval and overall survival of patients with T2\u2013T4,N0\u2013N3,M0 squamous cell carcinoma (SCC) of the oral cavity or oropharynx could be extended through the combination of surgery (and radiotherapy, if required) with perilymphatic recombinant IL\u20102 (rIL\u20102).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Patients with a resectable T2\u2013T4,N0\u2013N3,M0 SCC of the oral cavity and oropharynx were assigned randomly to receive surgery and radiotherapy or to receive IL\u20102, surgery, and radiotherapy. Five thousand units of rIL\u20102 were injected around the ipsilateral cervical lymph node chain daily for 10 days before surgery. After surgery, contralateral 5\u2010day rIL\u20102 courses were administered monthly for 1 year. The differences in disease free and overall survival between the two groups of patients were evaluated statistically.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Two hundred two patients finished the study. No significant complications related to rIL\u20102 were encountered, and surgery and radiotherapy were not hampered by its prior administration. Multivariate analysis conducted to determine the extent to which survival was influenced by rIL\u20102 and the other variables showed that rIL\u20102 significantly lengthened disease free survival (<jats:italic>P<\/jats:italic> &lt; 0.01) and that this resulted in longer overall survival (<jats:italic>P<\/jats:italic> &lt; 0.03).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The data emerging from this trial indicate that perilymphatic administration of low, nontoxic doses of rIL\u20102 is a simple and manageable way to delay recurrences of SCC. Cancer 2002;95:90\u20137. \u00a9 2002 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.10654<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.10654","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T19:33:49Z","timestamp":1030304029000},"page":"90-97","source":"Crossref","is-referenced-by-count":55,"title":["Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx"],"prefix":"10.1002","volume":"95","author":[{"given":"Antonella","family":"De Stefani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Forni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Ragona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Cavallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Bussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Usai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Badellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Cortesina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,6,28]]},"reference":[{"key":"e_1_2_6_2_2","volume-title":"Cytokine\u2010induced tumor immunogenicity. From exogenous molecules to gene therapy","author":"Forni G","year":"1994"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5699(97)80012-6"},{"key":"e_1_2_6_4_2","first-page":"3933","article-title":"Lymphokine\u2010activated tumor inhibition in vivo. The local administration of interleukin\u20102 triggers non\u2010reactive lymphocytes from tumor\u2010bearing mice to inhibit tumor growth","volume":"139","author":"Forni G","year":"1985","journal-title":"J Immunol."},{"key":"e_1_2_6_5_2","first-page":"187","volume-title":"Clinical applications of cytokines: role in pathogenesis, diagnosis and therapy","author":"Forni G","year":"1993"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19881215)62:12<2482::AID-CNCR2820621205>3.0.CO;2-9"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1994.104"},{"key":"e_1_2_6_8_2","first-page":"571","article-title":"Effect of low doses of interleukin\u20102 injected perilymphatically and peritumorally in patients with advanced primary head and neck squamous cell carcinoma","volume":"4","author":"Musiani P","year":"1989","journal-title":"J Biol Resp Modif."},{"key":"e_1_2_6_9_2","first-page":"702","article-title":"Infiltrating leukocyte populations and T\u2010lymphocyte subsets in head and neck squamous cell carcinomas from patients receiving perilymphatic injections of recombinant Interleukin\u20102. A pathological and immunophenotypical study","volume":"3","author":"Valente G","year":"1990","journal-title":"Mod Pathol."},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19860615)57:12<2295::AID-CNCR2820571211>3.0.CO;2-Q"},{"key":"e_1_2_6_11_2","first-page":"624","article-title":"The use of nitrogen mustard in the palliative treatment of carcinoma","volume":"1","author":"Karnofsky DA","year":"1949","journal-title":"Cancer."},{"key":"e_1_2_6_12_2","first-page":"81","article-title":"Cervical lymphography: difficulties and advantages","volume":"898","author":"Traissac L","year":"1968","journal-title":"Rev Laryngol."},{"key":"e_1_2_6_13_2","first-page":"5551","article-title":"In vivo interleukin 2\u2010induced activation of lymphokine\u2010activated killer cells and tumor cytotoxic T\u2010cells in cervical lymph nodes of patients with head and neck tumors","volume":"50","author":"Rivoltini L","year":"1990","journal-title":"Cancer Res."},{"key":"e_1_2_6_14_2","volume-title":"Trait\u00e8 de technique chirurgicale O.R.L. et cervico\u2010faciale","author":"Guerrier Y","year":"1980"},{"key":"e_1_2_6_15_2","volume-title":"Cancer of the head and neck","author":"Myers EN","year":"1989"},{"key":"e_1_2_6_16_2","volume-title":"Head and neck surgery","author":"Shah JP","year":"1996"},{"key":"e_1_2_6_17_2","volume-title":"Management of head and neck cancer. A multidisciplinary approach","author":"Million RR","year":"1994"},{"key":"e_1_2_6_18_2","volume-title":"BMDP statistical analysis","author":"BMDP","year":"1990"},{"key":"e_1_2_6_19_2","volume-title":"TNM classification of malignant tumours","author":"Sobin LH","year":"1997"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.2307\/2531201"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.44.1.7"},{"key":"e_1_2_6_22_2","first-page":"5654","article-title":"Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin\u20102 in patients with advanced squamous cell carcinoma of the head and neck","volume":"53","author":"Whiteside T","year":"1993","journal-title":"Cancer Res."},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.14.1049"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199603000-00005"},{"key":"e_1_2_6_25_2","first-page":"5469","article-title":"Local continuous high\u2010dose interleukin\u20102: new therapeutic model for treatment of advanced bladder carcinoma","volume":"49","author":"Huland E","year":"1986","journal-title":"Cancer Res."},{"key":"e_1_2_6_26_2","first-page":"5963","article-title":"Receptors for interleukin\u20102 on human squamous cell carcinoma cell lines and tumor in situ","volume":"52","author":"Weidmann E","year":"1992","journal-title":"Cancer Res."},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03259502"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.10654","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.10654","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T21:38:44Z","timestamp":1760305124000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.10654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6,28]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,7]]}},"alternative-id":["10.1002\/cncr.10654"],"URL":"https:\/\/doi.org\/10.1002\/cncr.10654","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,6,28]]}}}